AN
ANGO
ANGO AngioDynamics (ANGO) Q1 FY27 earnings call
A standard call that mixes a CEO succession announcement with a quarter showing the mix shift toward MedTech steadily lifting margins and narrowing losses. Management stuck with its outlook and leaned on NanoKnife disposables, Auryon share gains and AlphaVac momentum. Quality of the margin beat and cash cadence, plus execution under new leadership, are the open questions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.